Idebenone in senile dementia of Alzheimer type: a multicentre study
- PMID: 15374364
- DOI: 10.1016/0167-4943(92)90060-h
Idebenone in senile dementia of Alzheimer type: a multicentre study
Abstract
Idebenone is a new cerebro-active drug, effective in dementia disorders, particularly indicated in primary degenerative dementias, i.e. Alzheimer's disease. This new molecule acts as an electron trapper and a free radical scavenger protecting mitochondrial membranes from lipid peroxidation. A multicentric, double-blind trial of idebenone (45 mg twice daily orally) vs. placebo was carried out on 102 elderly patients affected by Alzheimer-type dementia of mild or moderate severity. Idebenone was administered for 4 consecutive months, 45 mg twice daily. Clinical evaluations were performed at the time of enrollment (t0) and monthly thereafter (t30, t60, t90 and t120) and at follow-up (t150 ). Tolerability to idebenone treatment was good and was associated with a statistically significant improvement of memory, attention and behaviour. It is worthwhile noting that these cognitive and behavioral findings were observed after the first month of treatment with enhancement evident in the following period.
Similar articles
-
Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly.Arch Gerontol Geriatr. 1992 Nov-Dec;15(3):261-9. doi: 10.1016/0167-4943(92)90061-8. Arch Gerontol Geriatr. 1992. PMID: 15374365
-
Donepezil for vascular cognitive impairment.Cochrane Database Syst Rev. 2004;(1):CD004395. doi: 10.1002/14651858.CD004395.pub2. Cochrane Database Syst Rev. 2004. PMID: 14974068 Review.
-
Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study.J Neural Transm Suppl. 1998;54:301-10. doi: 10.1007/978-3-7091-7508-8_30. J Neural Transm Suppl. 1998. PMID: 9850939 Clinical Trial.
-
A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease.Neuropsychobiology. 1997;36(2):73-82. doi: 10.1159/000119366. Neuropsychobiology. 1997. PMID: 9267856 Clinical Trial.
-
Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.Drugs Aging. 1994 Aug;5(2):133-52. doi: 10.2165/00002512-199405020-00007. Drugs Aging. 1994. PMID: 7981485 Review.
Cited by
-
Anti-Inflammatory Effects of Idebenone Attenuate LPS-Induced Systemic Inflammatory Diseases by Suppressing NF-κB Activation.Antioxidants (Basel). 2024 Jan 25;13(2):151. doi: 10.3390/antiox13020151. Antioxidants (Basel). 2024. PMID: 38397749 Free PMC article.
-
Nicotinamide ameliorates mitochondria-related neuronal apoptosis and cognitive impairment via the NAD+/SIRT3 pathway.Schizophrenia (Heidelb). 2023 May 20;9(1):32. doi: 10.1038/s41537-023-00357-w. Schizophrenia (Heidelb). 2023. PMID: 37210391 Free PMC article.
-
Disturb mitochondrial associated proteostasis: Neurodegeneration and imperfect ageing.Front Cell Dev Biol. 2023 Mar 10;11:1146564. doi: 10.3389/fcell.2023.1146564. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 36968195 Free PMC article. Review.
-
Idebenone Regulates Aβ and LPS-Induced Neurogliosis and Cognitive Function Through Inhibition of NLRP3 Inflammasome/IL-1β Axis Activation.Front Immunol. 2022 Feb 10;13:749336. doi: 10.3389/fimmu.2022.749336. eCollection 2022. Front Immunol. 2022. PMID: 35222363 Free PMC article.
-
Coenzyme Q10 effects in neurological diseases.Physiol Res. 2021 Dec 30;70(Suppl4):S683-S714. doi: 10.33549/physiolres.934712. Physiol Res. 2021. PMID: 35199552 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
